Kadimastem Ltd (KMSTF) Research

Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel.

Market snapshot

Symbol
KMSTF
Price
$3.21
Day change
-3.02%
Market cap
$125.7M
P/E ratio
-2.35x
52-week range
0.6404-9.07082
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • American Hemp Ventures, Inc. (AMHV)
  • Antisense Therapeutics Limited (ATHJF)
  • OKYO Pharma Limited (EMMLF)
  • Noxopharm Limited (NOXOF)
  • Organicell Regenerative Medicine, Inc. (OCEL)
  • OptiBiotix Health Plc (OPBXF)
  • PharmChem, Inc. (PCHM)
  • Renalytix Plc (RTNXF)

Open Kadimastem Ltd (KMSTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.